There was a significant trend in increased median survival in those < 80 on continuous Tafamidis compared to those who were initially in the placebo treatment group.
← all excerpts
Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence.
1
—
—